Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate Enlargement
Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate Enlargement
The primary objectives were to determine the efficacy and safety of the GITS formulation of
 Doxazosin in Taiwanese patients with prostate enlargement.
Inclusion Criteria:

 -  Taiwanese male subjects between 50 and 80 years of age who had: a primary diagnosis of
 BPH, defined as having an enlarged prostate (confirmed by digital rectal examination
 [DRE] and/or B-mode ultrasound); an IPSS score of ≥12; and a Qmax in the range of 5 to
 15 mL/sec in a total voided volume of ≥150 mL, were eligible for the study.

 Exclusion criteria include but not limited to:

 -  Previous prostate surgery, presence of a prostate stent or microwave thermotherapy
 and/or balloon dilatation within the previous 6 months

 -  Concomitant therapy or previous therapy within 14 days with agents known to affect
 bladder or urethral function.